
Pro-Dex (PDEX) Stock Forecast & Price Target
Pro-Dex (PDEX) Analyst Ratings
Bulls say
Pro-Dex Inc. has demonstrated a robust financial performance, with year-over-year revenue growth of 22%, primarily fueled by increased sales from new medical device products and repair services. Additionally, the company has achieved a gross margin of 33%, reflecting effective cost management and operational efficiency. Strategic investments in private label products and winning new product contracts further position Pro-Dex for continued growth in the highly competitive medical device sector.
Bears say
The financial outlook for Pro-Dex Inc indicates a downward revision in estimates for FY25, with revenue projections decreasing from $68 million to $67 million and EPS adjusted down from $2.30 to $2.81. This adjustment signals potential challenges in achieving revenue growth and profitability targets, which may hinder investor confidence. Additionally, the company faces significant risks related to fluctuating demand for technology, competition in the market, and adverse macroeconomic factors that could further affect its financial performance.
This aggregate rating is based on analysts' research of Pro-Dex and is not a guaranteed prediction by Public.com or investment advice.
Pro-Dex (PDEX) Analyst Forecast & Price Prediction
Start investing in Pro-Dex (PDEX)
Order type
Buy in
Order amount
Est. shares
0 shares